Plain-English translation of NCT06055816 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a three-drug combination called gemcitabine combined with for older adults who have been diagnosed with locally advanced nasopharyngeal cancer (a type of throat cancer). The study gives patients the medication before they receive standard radiation therapy to see if this approach helps shrink tumors and improve outcomes. The treatment is designed specifically for people aged 65 and older.
Older adults with advanced throat cancer often have limited treatment options and may not tolerate standard chemotherapy well. This trial is exploring whether this new medication combination can be safer and more effective for this age group, potentially offering better chances of controlling the cancer.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the three-drug combination every 3 weeks for 3 cycles (about 9 weeks total) before starting radiation therapy. During radiation, you will continue to receive one of the medications (endostar) to work alongside your radiation treatments. You will have regular clinic visits for blood tests, scans, and physical exams to monitor how well the treatment is working and to check for any side effects. The study involves about 40 participants total and is being conducted at Zhejiang Cancer Hospital in China.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Zhejiang Cancer Hospital
Enrollment target
~40 participants
Started
September 2023
Primary completion
September 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
65 Years and older
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaozhong Chen
Department of Radiation Oncology, Zhejiang Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.